Imaging is poised to play a key role in the advancement of 21st-century science and healthcare, but only if the radiology community changes its view of imaging sciences, according to Dr. Elias Zerhouni, director of the National Institutes of Health. If that means researchers adopting unconventional or innovative approaches, so be it.
Imaging is poised to play a key role in the advancement of 21st-century science and healthcare, but only if the radiology community changes its view of imaging sciences, according to Dr. Elias Zerhouni, director of the National Institutes of Health. If that means researchers adopting unconventional or innovative approaches, so be it.
"The greatest risk in science is to stop taking risks. Let radiologists become what they were before - great risk-takers," Zerhouni said during a session on the future of biomedical imaging and imaging research at the European Congress of Radiology.
One of the greatest weaknesses in medical research is the inability to study complexity, he said. This looks set to change as science moves toward systems biology. Investigators in the future will look at disease pathways, not single diseases, and at multiple drug targets. They will study fundamental disease mechanisms, such as inflammation or apoptosis, rather than specific conditions, like arthritis or cancer.
This change in approach will mean a move away from qualitative, unidimensional, nonspecific information.
"We are talking about quantitative, nondestructive, spatially and temporally resolved data. All of these words say 'imaging' to me," he said. "Imaging is the science of extracting spatially and temporally resolved relevant biological information. That's what we do."
Imaging will be relevant to every measurement length scale: angstroms, microns, and meters, Zerhouni said. Existing imaging technologies currently struggle to resolve structures in the 100 to 500-nm range, such as complex macromolecular systems. Researchers are working to plug this gap.
He predicts that over the next 20 years imaging researchers will continue their efforts to detect subclinical disease. He would like radiologists to develop imaging-based in vivo biomarkers that could assist in the study of treatments for long-term chronic diseases. Image-guided intervention and microsampling for disease characterization is another large area ripe for radiology research.
Zerhouni envisages this research endeavour as being truly global, and he is keen to foster international collaborations. The NIH will this year invest approximately $1 billion in scientific research outside the U.S. and in collaborative projects with non-U.S. partners. More than 50% of the NIH's partnership projects involve European countries.
"Science advances so fast that any barriers between scientists are an impediment to progress," he said. "In the future, imaging sciences will have to have an international collaborative framework that is easy to travel."
Speaking at the same session, Dr. Liselotte Højgaard, chair of the European Medical Research Council (EMRC), reiterated the importance of international collaboration in imaging research. The EMRC is looking at ways to reciprocate the generosity that the NIH shows to European researchers, she said.
At the moment, however, Europe lags behind the U.S. in terms of R&D investment. In the U.S., 2.6% of gross domestic product is channeled toward R&D, compared with 1.9% in the European Union. Sources for funding are also fragmented, with just 7% to 8% of EU R&D investment coming from the centralized framework funding program. The remainder is provided by national agencies, industry, and charities.
Højgaard encouraged ECR delegates to take advantage of funding opportunities for research. She also welcomed initiatives designed to unite imaging researchers from different backgrounds, such as the newly formed European Institute for Biomedical Imaging Research. She advised radiologists not to become restricted to any one or two methods, but to consider all available tools and techniques that could assist in answering their clinical questions.
"Some radiologists are very much in love with their own methodology and don't look at the methodology next door. They are either a CT person, a PET person, or an MRI person," she said. "Perhaps we should instead be organ experts, so we know, for example, about all the different modalities that could be used for brain imaging.
For more online information, visit Diagnostic Imaging's ECR 2007 Webcast.
Enhancing Lesions on Breast MRI: Can an Updated Kaiser Scoring Model Improve Detection?
September 26th 2024The addition of parameters such as patient age, MIP sign and associated imaging features to the Kaiser score demonstrated a 95.6 percent AUC for breast cancer detection of enhancing lesions on breast MRI in recently published research.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.